UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN(TM) Gene Therapy to Treat Wounds in Painful Skin Disorder

Stock Information for Leap Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Leap Therapeutics Inc.

ZEVASKYN(TM) Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area
Bio-Techne's Simple Western(TM) Technology Utilized in Recent FDA Approval of ZEVASKYN(TM) Cell-Based Gene Therapy
Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million
Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index
Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL(TM) Study Data in Recessive Dystrophic Epidermolysis Bullosa
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.